Investigational Drug Information for MEK162
✉ Email this page to a colleague
What is the drug development status for MEK162?
MEK162 is an investigational drug.
There have been 71 clinical trials for MEK162.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 12th 2013.
The most common disease conditions in clinical trials are Melanoma, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Array BioPharma, National Cancer Institute (NCI), and Pfizer.
Summary for MEK162
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,526 |
| WIPO Patent Applications | 1,178 |
| Japanese Patent Applications | 461 |
| Clinical Trial Progress | Phase 3 (2013-07-12) |
| Vendors | 80 |
Recent Clinical Trials for MEK162
| Title | Sponsor | Phase |
|---|---|---|
| Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial | National Cancer Institute (NCI) | Phase 2 |
| Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial | National Cancer Institute (NCI) | Phase 2 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Registration Trial | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for MEK162
Top disease conditions for MEK162
Top clinical trial sponsors for MEK162
US Patents for MEK162
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
